Artan Biotechnologies
- Company typePrivate
- Founded2023
- HeadquartersSt. Petersburg, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Artan Biotechnologies firmographics
Firmographics- Name
- Artan Biotechnologies
- Legal name
- Artan Biotechnologies LLC
- Website
- https://artan.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Artan Biotechnologies industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Artan Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- St. Petersburg
- HQ country
- United States
- HQ region
- North America
Markets served
Artan Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Therapeutic Development and Commercialization: As a pre-commercial biotechnology company, Artan is developing a pipeline of tRNA suppressor therapies for rare diseases and aging. Revenue would be generated through eventual therapeutic product sales following regulatory approval, or through licensing/partnership deals with larger pharmaceutical companies for development and commercialization rights.
Go-to-market motion1 record
Marketing channels3 records
Artan Biotechnologies product offering
Product offeringCore offering
Artan Biotechnologies is developing a proprietary engineered tRNA suppressor system that specifically recognizes premature stop codons introduced by nonsense mutations and restores normal protein translation, producing full-length functional proteins rather than truncated nonfunctional ones. The pipeline targets rare genetic diseases and age-related conditions whose underlying etiology is premature translation termination, with the modality positioned for eventual out-licensing or partnership-based development and commercialization.
Product overview
Artan Biotechnologies is developing a single unified product: an engineered tRNA suppressor system that targets nonsense mutations. The company's approach involves engineered suppressor molecules that specifically recognize premature stop codons and restore normal protein translation, addressing the root cause of genetic and age-related diseases. The pipeline focuses on this novel codon suppressor technology rather than a platform-plus-modules architecture.
Differentiator
Problem solved
Functional benefit
Products and services
- tRNA Suppressor System An engineered suppressor system that specifically recognizes nonsense mutation codons and restores normal protein translation, producing full-length functional proteins instead of truncated nonfunctional ones. Targeted at rare genetic and age-related diseases caused by premature translation termination.
Companies that use Artan Biotechnologies
Customer profileSegments1 record
Ideal customer profiles1 record
Artan Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Artan Biotechnologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- VitaDAOminorArtan is listed as being in partnership with VitaDAO, a decentralized science (DeSci) organization focused on longevity research. VitaDAO operates as a DAO that funds and accelerates research in the longevity and life-extension space, making it a strategic partner aligned with Artan's focus on aging-related diseases.
Scale indicators1 record
Recent moves3 records
Expansion highlights4 records
Artan Biotechnologies competitors and assessment
Company assessmentDirect peers
- PTC Therapeutics: PTC's ataluren targets nonsense-mutation readthrough across multiple genetic indications (e.g., Duchenne muscular dystrophy, cystic fibrosis), making it a direct disease-area and mechanism competitor to Artan's codon-suppressor strategy.
- Eloxx Pharmaceuticals: Eloxx pursued small-molecule readthrough of nonsense mutations in genetic diseases, the same disease-causing mechanism Artan's engineered tRNAs address, though via a pharmacological rather than RNA-therapeutic approach.
- ProQR Therapeutics: ProQR develops Axiomer RNA-editing oligonucleotides to correct pathogenic mutations, sharing Artan's focus on RNA-based therapeutics for rare genetic diseases and similar target-patient populations.
- Tevard Biosciences: Tevard is developing engineered tRNA-based therapeutics to suppress premature stop codons caused by nonsense mutations in genetic diseases, making it the closest mechanistic and disease-area peer to Artan.
Broad incumbents
- Moderna: Moderna's mRNA platform spans vaccines, protein-replacement and rare-disease therapeutics, including programs that address nonsense mutations; it is an RNA-therapeutics incumbent against whose broader pipeline Artan would compete for capital and partnerships.
- Translate Bio (Sanofi): Acquired by Sanofi, Translate Bio is a leading mRNA therapeutics platform for genetic and rare diseases, providing a large-incumbent reference point for valuation and platform breadth in the RNA-therapeutics space Artan occupies.
Emerging players
- Beam Therapeutics: Beam develops base-editing therapies for genetic diseases; targeting the same underlying mutation-driven mechanisms via a different modality makes it a relevant adjacent peer in the rare-disease RNA/DNA therapeutics category.
- ReCode Therapeutics: ReCode is an early-stage biotech developing mRNA and tRNA-based therapeutics for rare genetic diseases including cystic fibrosis, putting it in overlapping nonsense-mutation and RNA-therapeutic territory with Artan.
- Prime Medicine: Prime Medicine's prime editing platform targets genetic disease mutations, competing for the same patient populations and pharma partnership dollars that an Artan tRNA suppressor program could attract.
Others
- VitaDAO: VitaDAO is the decentralized science organization funding longevity and aging-related research that is explicitly partnered with Artan, making it a key ecosystem/capital-formation peer rather than a therapeutic competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Artan Biotechnologies social profiles
Digital presenceArtan Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Artan Biotechnologies leadership team
Management profileNumber of profiles
Profiles2 records
Artan Biotechnologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Artan Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Artan Biotechnologies
What does Artan Biotechnologies do?
Artan Biotechnologies is developing a proprietary engineered tRNA suppressor system that specifically recognizes premature stop codons introduced by nonsense mutations and restores normal protein translation, producing full-length functional proteins rather than truncated nonfunctional ones. The pipeline targets rare genetic diseases and age-related conditions whose underlying etiology is premature translation termination, with the modality positioned for eventual out-licensing or partnership-based development and commercialization.
Is Artan Biotechnologies a public or private company?
Artan Biotechnologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Artan Biotechnologies founded?
Artan Biotechnologies was founded in 2023. It employs 1 to 10 people.
Where is Artan Biotechnologies based?
Artan Biotechnologies is headquartered in St. Petersburg, United States, in the North America region.
How does Artan Biotechnologies make money?
One revenue line is on record: therapeutic Development and Commercialization.
Who are Artan Biotechnologies's main competitors?
Direct peers on record are PTC Therapeutics, Eloxx Pharmaceuticals, ProQR Therapeutics and Tevard Biosciences. Broad incumbents are Moderna and Translate Bio (Sanofi). Emerging players are Beam Therapeutics, ReCode Therapeutics and Prime Medicine. VitaDAO is listed as an others.
Does Artan Biotechnologies have an API?
No public API is recorded for Artan Biotechnologies.
What industry is Artan Biotechnologies in?
Artan Biotechnologies's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2834.